• ABOUT
  • THE GROUP
  • NEWS & MEDIA
  • EVENTS
  • CAREER
  • CONTACT US
  • 0

AneuVysion

More Views

AneuVysion
AneuVysion, which utilizes patented fluorescence in situ hybridization (FISH) technology applied to uncultured amniocytes, provides detection of trisomies 13, 18, and 21 (Down syndrome) and sex chromosome aneusomies in as little as 24 hours.
Read More
Add to Shortlist

Features & Benefits

  • The results are rapidly available, within 24 hours after the amniocentesis sample is received in the laboratory (rather than 7-22 days for routine chromosome analysis)
  • The availability of AneuVysion results along with consistent clinical information (i.e., fetal anomalies detected by ultrasonography) allows for pregnancy management options that otherwise might not be available due to late gestational age.
  • In the rare case of a culture failure when standard cytogenetic results cannot be obtained, information on chromosome number for the most likely aneusomies is available.

Product Details

AneuVysion, which utilizes patented fluorescence in situ hybridization (FISH) technology applied to uncultured amniocytes, provides detection of trisomies 13, 18, and 21 (Down syndrome) and sex chromosome aneusomies in as little as 24 hours. Together these conditions account for nearly twothirds of all abnormalities identified at the time of amniocentesis, and 85-90% of clinically significant chromosomal abnormalities detected in live-born infants. Review of AneuVysion testing of over 29,000 amniotic fluid samples has found that the test is 99.9% accurate for the detection of trisomies 13, 18, 21, and aneusomies of X and Y.
Read More